Role of EXT1 and glycosaminoglycans in the early stage of filovirus entry

Journal of Virology

Volumn 89, Issue 10, 2015, Pages 5441-5449

  O'Hearn, Aileen ^a,b   Wang, Minxiu ^a   Cheng, Han ^a   Lear Rooney, Calli M ^b   Koning, Katie ^a   Rumschlag Booms, Emily ^a   Varhegyi, Elizabeth ^a   Olinger, Gene ^b   Rong, Lijun ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXOSTOSIN 1; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; EXOSTOSIN-1; HEPARIN; N ACETYLGLUCOSAMINYLTRANSFERASE; VIRUS RECEPTOR;

ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; EXOSTOSIN 1 GENE; GENE SILENCING; GENE TARGETING; HOST CELL; HUMAN; HUMAN CELL; MARBURG VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE CULTURE CELL; VIRUS ENTRY; VIRUS GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DEFICIENCY; EBOLAVIRUS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; MARBURGVIRUS; MOUSE; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRULENCE;

ANIMALIA; EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MARBURGVIRUS;

ANIMALS; CELL LINE; EBOLAVIRUS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GENE KNOCKDOWN TECHNIQUES; GLYCOSAMINOGLYCANS; HEK293 CELLS; HEPARIN; HEPARITIN SULFATE; HOST-PATHOGEN INTERACTIONS; HUMANS; MARBURGVIRUS; MICE; N-ACETYLGLUCOSAMINYLTRANSFERASES; RECEPTORS, VIRUS; VIRAL PROTEINS; VIRULENCE; VIRUS INTERNALIZATION;

EID: 84928555554     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03689-14     Document Type: Article

References (42)

1. Feldmann F, Sanchez A, Geisbert JB. 2013. Filoviridae: Marburg and Ebola viruses, p 923-956. In Knipe DM, Howley PM (ed), Fields virology, 6th ed, vol 2. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, PA.
2. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53. http://dx.doi.org/10.1038/nature13777.
3. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402-405. http://dx.doi.org/10.1038/nature13027.
4. Kortepeter MG, Bausch DG, Bray M. 2011. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 204(Suppl 3):S810-S816. http://dx.doi.org/10.1093/infdis/jir299.
5. Roddy P, Colebunders R, Jeffs B, Palma PP, Van Herp M, Borchert M. 2011. Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options. J Infect Dis 204(Suppl 3):S791-S795. http://dx.doi.org/10.1093/infdis/jir297.
6. Kuhn JH, Radoshitzky SR, Guth AC, Warfield KL, Li W, Vincent MJ, Towner JS, Nichol ST, Bavari S, Choe H, Aman MJ, Farzan M. 2006. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 281:15951-15958. http://dx.doi.org/10.1074/jbc.M601796200.
7. Manicassamy B, Wang J, Jiang H, Rong L. 2005. Comprehensive analysis of Ebola virus GP1 in viral entry. J Virol 79:4793-4805. http://dx.doi.org/10.1128/JVI.79.8.4793-4805.2005.
8. Manicassamy B, Wang J, Rumschlag E, Tymen S, Volchkova V, Volchkov V, Rong L. 2007. Characterization of Marburg virus glycoprotein in viral entry. Virology 358:79-88. http://dx.doi.org/10.1016/j.virol.2006.06.041.
9. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA. 2010. Cellular entry of Ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog 6(9):e1001110. http://dx.doi.org/10.1371/journal.ppat.1001110.
10. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Cin PD, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343. http://dx.doi.org/10.1038/nature10348.
11. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. 2011. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 77: 344-348. http://dx.doi.org/10.1038/nature10380.
12. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, McCray PB, Jr, Chiorini J, Maury W. 2011. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A 108:8426-8431. http://dx.doi.org/10.1073/pnas.1019030108.
13. Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K. 2012. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J 31:1947-1960. http://dx.doi.org/10.1038/emboj.2012.53.
14. Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST. 2005. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332:20-27. http://dx.doi.org/10.1016/j.virol.2004.10.048.
15. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69:6705-6711.
16. Manicassamy B, Rong L. 2009. Expression of Ebolavirus glycoprotein on the target cells enhances viral entry. Virol J 6:75. http://dx.doi.org/10.1186/1743-422X-6-75.
17. Guo Y, Rumschlag-Booms E, Wang J, Xiao H, Yu J, Wang J, Guo L, Gao GF, Cao Y, Caffrey M, Rong L. 2009. Analysis of hemagglutininmediated entry tropism of H5N1 avian influenza. Virol J 6:39. http://dx.doi.org/10.1186/1743-422X-6-39.
18. McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, Tufaro F. 1998. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 19:158-161. http://dx.doi.org/10.1038/514.
19. Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. 1998. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 273:26265-26268. http://dx.doi.org/10.1074/jbc.273.41.26265.
20. Wang M, Tscherne DM, McCullough C, Caffrey M, Garcia-Sastre A, Rong L. 2012. Residue Y161 of influenza virus hemagglutinin is involved in viral recognition of sialylated complexes from different hosts. J Virol 86:4455-4462. http://dx.doi.org/10.1128/JVI.07187-11.
21. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R. 2002. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76:6841-6844. http://dx.doi.org/10.1128/JVI.76.13.6841-6844.2002.
22. Becker S, Spiess M, Klenk HD. 1995. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol 76(Part 2):393-399.
23. Chan SY, Empig CJ, Welte FJ, Speck RF, Schmaljohn A, Kreisberg JF, Goldsmith MA. 2001. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106:117-126. http://dx.doi.org/10.1016/S0092-8674(01)00418-4.
24. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645. http://dx.doi.org/10.1126/science.1110656.
25. Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, Jones S, Feldmann H, Kawaoka Y. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 80:10109-10116. http://dx.doi.org/10.1128/JVI.01157-06.
26. Takada A, Fujioka K, Tsuiji M, Morikawa A, Higashi N, Ebihara H, Kobasa D, Feldmann H, Irimura T, Kawaoka Y. 2004. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 78:2943-2947. http://dx.doi.org/10.1128/JVI.78.6.2943-2947.2004.
27. Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103. http://dx.doi.org/10.1006/viro.2000.0546.
28. de Boer SM, Kortekaas J, de Haan CA, Rottier PJ, Moormann RJ, Bosch BJ. 2012. Heparan sulfate facilitates Rift Valley fever virus entry into the cell. J Virol 86:13767-13771. http://dx.doi.org/10.1128/JVI.01364-12.
29. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75: 1565-1570. http://dx.doi.org/10.1128/JVI.75.3.1565-1570.2001.
30. Harris J, Werling D. 2003. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol 5:671-680. http://dx.doi.org/10.1046/j.1462-5822.2003.00313.x.
31. Heil ML, Albee A, Strauss JH, Kuhn RJ. 2001. An amino acid substitution in the coding region of the E2 glycoprotein adapts Ross River virus to utilize heparan sulfate as an attachment moiety. J Virol 75:6303-6309. http://dx.doi.org/10.1128/JVI.75.14.6303-6309.2001.
32. Jackson T, Ellard FM, Ghazaleh RA, Brookes SM, Blakemore WE, Corteyn AH, Stuart DI, Newman JW, King AM. 1996. Efficient infection of cells in culture by typeOfoot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 70:5282-5287.
33. Letian T, Tianyu Z. 2010. Cellular receptor binding and entry of human papillomavirus. Virol J 7:2. http://dx.doi.org/10.1186/1743-422X-7-2.
34. Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski H, Norcross MA. 1995. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 69:2233-2239.
35. Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG. 1992. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 116:1273-1281. http://dx.doi.org/10.1083/jcb.116.5.1273.
36. Smit JM, Waarts BL, Kimata K, Klimstra WB, Bittman R, Wilschut J. 2002. Adaptation of alphaviruses to heparan sulfate: interaction of Sindbis and Semliki forest viruses with liposomes containing lipidconjugated heparin. J Virol 76:10128-10137. http://dx.doi.org/10.1128/JVI.76.20.10128-10137.2002.
37. Spear PG. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 6:401-410. http://dx.doi.org/10.1111/j.1462-5822.2004.00389.x.
38. WuDunn D, Spear PG. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 63:52-58.
39. Salvador B, Sexton NR, Carrion R, Jr, Nunneley J, Patterson JL, Steffen I, Lu K, Muench MO, Lembo D, Simmons G. 2013. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol 87:3295-3304. http://dx.doi.org/10.1128/JVI.01621-12.
40. Gandhi NS, Mancera RL. 2008. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72:455-482. http://dx.doi.org/10.1111/j.1747-0285.2008.00741.x.
41. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. 2003. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188:1618-1629. http://dx.doi.org/10.1086/379724.
42. Gear JS, Cassel GA, Gear AJ, Trappler B, Clausen L, Meyers AM, Kew MC, Bothwell TH, Sher R, Miller GB, Schneider J, Koornhof HJ, Gomperts ED, Isaacson M, Gear JH. 1975. Outbreake of Marburg virus disease in Johannesburg. Br Med J 4:489-493. http://dx.doi.org/10.1136/bmj.4.5995.489.